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Background: Glycolysis in presence of oxygen with high glucose consumption is known to be the metabolism of
choice in many tumors. In lung cancer this phenomenon is routinely exploited in diagnostic PET imaging of
fluorodeoxyglucose uptake, but not much is known about the prognostic capabilities of glycolysis level assessment
in resected lung tumor samples.
Methods: In this retrospective study, we used real time polymerase chain reaction(RQ-PCR) to assess the expression
level of the gene for Glyceraldehyde 3-phosphate dehydrogenase(GAPDH), key enzyme for glucose breakdown, in
tumor samples from 82 consecutive early stages resected non small cell lung cancer(NSCLC) patients. We then
compared our results in six large publicly available NSCLC microarray datasets collecting data from over 1250 total
patients.
Results: In our study GAPDH gene over expression was found to be an adverse prognostic factor in early stages
NSCLC (n = 82 HR = 1.30 p = 0.050). This result was confirmed in 5 of 6 public datasets analyzed: Shedden et al.
2008: n = 442 HR = 1.54 p < 0.0001; Lee et al. 2008: n = 138 HR = 1.31 p = 0.043; Tomida et al. 2009: n = 117 HR = 1.59
p = 0.004; Roepman et al. 2009: n = 172 (TPI1 gene) HR = 1.51 p = 0.009; Okayama et al. 2012: n = 226 HR = 3.19 p < 0.0001;
Botling et al. 2013: n = 196 HR = 1.00 p = 0.97). Furthermore, in the large and clinically well annotated Shedden et al.
microarray dataset, GAPDH hazard ratio did not change whether calculated for the whole dataset or for the subgroup of
adjuvant naive patients only (n = 330 HR = 1.49 p < 0.0001).
Conclusion: GAPDH gene over expression in resected tumor samples is an adverse prognostic factor in NSCLC. Our results
confirm the prognostic value of glucose metabolism assessment in NSCLC.
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Cancer cell metabolism characterized by high glycolysis
rate in presence of oxygen has been confirmed in many
tumors [1]. This phenomenon, discovered by O. War-
burg in 1924 [2] and once considered as the result of a
“damaged” metabolism [3], has presently been found
also in many rapidly multiplying non-cancerous cells,* Correspondence: roberto.puzone@yahoo.it
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reproduction in any medium, provided the orleading to an increased focus of cancer research on the
specific characteristics of tumor metabolism [4].
This field of cancer research is promising. In fact the high
glycolysis rate in tumors, as assessed by diagnostic positron
emission tomography (PET) imaging of fluorodeoxyglucose
(FDG) uptake, is also exploited in clinical practice, in the
differential diagnosis of nodules of unknown origin, and,
more recently, also in prognostic studies [5-7]. However,
specific investigations must be performed because we can
expect that tumors with different characteristics-origin,
grow dynamics, etc.-have different metabolic requirements.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 IST patient’s characteristics
Characteristics Number (%)
Number of patients 82
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NSCLC, the most frequent histological type of lung
cancer (still the leading cause of cancer death in the
world [8]). There is evidence that high glucose metab-
olism is present in NSCLC, so a role of metabolism as
prognostic factor can be hypothesized; in fact this role
is actually investigated in lung cancer by the assess-
ment of FDG uptake level [6,9,10].
New effective prognostic factors could be very useful
for NSCLC patients. Presently, pathological stage of the
resected tumor is the main prognostic factor used in
clinical practice to select NSCLC patients to be referred
for additional therapies after surgery [11], but many
early staged patients actually relapse [12]. In fact, many
proteins or genes, differently expressed in tumor sam-
ples from patients with different survivals, are investi-
gated as possible prognostic biomarkers; but NSCLC is
probably a very heterogeneous disease [13] and this
could justify the high number of mostly non-overlapping
gene lists proposed as prognostic signatures [14]. How-
ever, PET effectiveness in distinguishing NSCLC from
non-tumor lung tissue suggests that genes related to glu-
cose metabolism bear an important role in all NSCLC,
regardless of tumor heterogeneity.
Among these genes, GAPDH has an essential role in glu-
cose metabolism, where the corresponding enzyme converts
glyceraldehydes-3-phosphate to 1,3-diphosphoglycerate with
reduction of nicotinamide adenine dinucleotide (NAD+) to
NADH. In fact GAPDH gene is expressed in all tissue, so to
be classically used as housekeeping gene, but it is
known to be over expressed in many tumors as com-
pared to normal tissues, and also to be correlated with
poor prognosis or tumor aggressiveness in ovarian,
breast, renal, colorectal, melanoma cancer [15]. Fur-
thermore, GAPDH protein is able to bind to RNA and
DNA, supporting glycolytic and extra-glycolytic regu-
latory roles in cell stress, apoptosis, and metabolism
[16-18]. In lung cancer, GAPDH protein is well known
to be over expressed as compared to normal lung tis-
sue [19], and GAPDH gene is known to be expressed
at high levels as compared to the surrounding non
cancerous lung biopsies [20]. However, while evidences
accumulate that preoperative FDG uptake level is a
prognostic factor in NSCLC, the prognostic value of
GAPDH expression level in resected NSCLC samples is
still to be assessed. In this retrospective study, we mea-
sured GAPDH gene expression, by RQ-PCR, on tumor
samples from a group 82 resected NSCLC patients.
After detecting a significant correlation of GAPDH
with survival from our patient follow-up data, we de-
cided to further investigate the expression of GAPDH
gene in six large publicly available NSCLC microarray
datasets, collecting data from over 1250 total NSCLC
patients.Methods
Study population
Our study included 82 consecutive patients, stage I-III
NSCLC, who had undergone radical surgical resection at
National Institute for Cancer Research, Genoa, Italy
(IST) between July 2005 and March 2007. All tumors
were surgically removed without microscopic residual
disease. None of the patients received adjuvant radio-
therapy or chemotherapy. Follow up period lasted from
July 2005 to December 2010 and survival time was com-
puted from the date of surgery. Informed written con-
sent from the patients and approval of our institute
(IST) Bioethics Board were obtained. Patient and tumor
characteristics are in Table 1.
Reverse transcription and RQ-PCR
RNA was isolated from paraffin-embedded tumor samples
using the High Pure FFPE RNA Micro Kit (Roche Applied
Science, Mannheim, Germany) with minor modifications.
RNA were reverse-transcribed with SuperScript™ II RT
(Invitrogen, Grand Island, NY, USA) according to the
manufacturer’s instructions. Resulting cDNA was ampli-
fied by the LightCycler 480 Real Time PCR System II
(Roche Applied Science). Relative gene expression levels
were calculated using the Qgene software [21] featuring
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Beta-2-microglobulin (B2M) and beta-glucuronidase (GUSB)
were used as housekeeping genes and a virtual housekeeping
gene was calculated using BestKeeper software [22]. PCR
primer sequences are reported in Additional file 1.
Statistical analysis
Overall survival analysis for GAPDH RQ-PCR gene ex-
pression, with hazard ratio (HR) and confidence interval
(CI) calculation, were performed on our patient data by
using the Cox regression model. Multivariate Cox re-
gression was performed with adjusting for tumor stage
categorized in 3 classes (I – II - III). The Kaplan-Meier
curve was plotted by separating patients on the median
GAPDH gene expression level. Cumulative survivals
were assessed by the Kaplan-Meier model. All calcula-
tions and plots were performed by using R 2.14(64bit)
software [23]. Gene expression, survival data and sample
R code are reported in Additional file 1.
Comparison with the public microarray datasets
Six publicly available NSCLC microarrays datasets were
used: Shedden et al. [24] (Sh2008) downloaded from
https://array.nci.nih.gov/caarray/project/details.action?
project.id=182; GSE8894, Lee et al. [25] (Le2008);
GSE13213, Tomida et al. [26] (To2009); Roepman
et al. [27] (Ro2009) downloaded from http://research.
agendia.com (free registration is requested, but for
profit usage or redistribution of data is not allowed);
GSE31210, Okayama et al. [28] (Ok2012); GSE37745,
Botling et al. [29] (Bo2013). Unless otherwise specified
datasets were downloaded from GEO repository at
http://www.ncbi.nlm.nih.gov/geo/. Full patient and tumor
characteristics are in cited papers; a summary of dataset
characteristics, and our patient data for comparison, is in
Table 2. Datasets were chosen as being large (patients
number N > 100), recent (year > =2008) and featuringTable 2 Summary of characteristics of the public microarray d
Dataset (year) Patient
number
Age median (min-max) Stage
IST (2012) 82 69 (47–82) 44-1
[24] Shedden et al. (2008)
all patients
442 65 (33–87) 276-9
[24] Shedden et al. (2008)
adjuvant-naïve
330 65 (33–87) 230-6
[25] Lee et al. (2008) 138 62 (13–82) n.
[26] Tomida et al. (2009) 117 61 (32–84) 79-1
[27] Roepman et al. (2009) 172 54 (22–79) 117-
[28] Okayama et al. (2012) 226 61 (30–76) 168-
[29] Botling at al. (2013) 196 65 (39–84) 130-3
*custom annotation provided.adequate clinical and pathological data publicly available.
For all datasets but Sh2008, we downloaded the gene ex-
pression matrix file (or equivalent files provided) with
clinical and pathological data. For the Sh2008 dataset-
actually the largest, and provided with high quality clinical
and pathological data-we calculated the gene expression
matrix from the “CEL” files provided, using standard
Methods (GCRMA [30], filtering, normalization, bias cor-
rections [31]). For this dataset two separate analysis were
performed, by including (N = 442) or excluding (N = 330)
the patients that had received adjuvant therapy, in order
to investigate if adjuvant treatment presence could con-
found GAPDH HR results. In fact, our patients had not re-
ceived adjuvant treatments but, in most of the microarray
datasets, no information about adjuvant treatments was
available at patient level.
Statistical analysis for the datasets was performed
similarly as for our patient RQ-PCR data. A single
GAPDH gene level was calculated for each patient sam-
ple as the mean level of all its probes mapped to
GAPDH. Stage was categorized in 3 classes (I-II-III) or 2
classes (I – II + III) when patient numbers were low in
higher stages. For the Le2008 dataset, relapse free sur-
vival data was used in regressions due to overall survival
data unavailability. For the Ro2009 dataset, a large and
clinically well annotated dataset, the probe annotation
file had no GAPDH gene reference; we decided to use, at
least in part, this dataset in the present work by analyz-
ing the gene expression for the strictly metabolically re-
lated triosephosphate isomerase 1 (TPI1), that was found
in fact highly correlated with GAPDH gene in all other
microarray datasets (Pearson's r > 0.79 for GAPDH-TPI1
expression levels). Also, patient characteristics and clinical
data accuracy were diverse among the microarray datasets;
so we performed the survival analysis separately for each
microarray dataset, and reported the results using a forest







5-23 ADK SCC other 0.54 (.44-.66) RQ-PCR
6-69 ADK 0.55 (.50-.60) Affymetrix U133a
0-40 ADK 0.60 (.55-.66) Affyimetrix U133a
a. ADK SCC 0.50 (.42-.59) Affymetrix U133plus2
3-25 ADK 0.66 (.58-.75) Agilent 44k
55-0 ADK SCC other 0.65 (.57-.74) Agilent 44k*
58-0 ADK 0.84 (.79-.89) Affymetrix U133plus2
5-31 ADK SCC 0.42 (.35-.49) Affymetrix U133plus2
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performed by using R 2.14(64bit) software [23] and
Bioconductor libraries [33].
Results
GAPDH gene expression level and correlation with
survival in our patients
Patient and cancer characteristics are reported in Table 1.
None of the 82 patients was lost to follow-up. During a
median follow-up time of 5 years, 37 (45%) deaths were
observed; cumulative survival was 89%, 73%, 65%, 56%
and 54%, respectively at 1, 2, 3, 4 and 5 years. In univari-
ate analysis age, sex, or smoking history had no correl-
ation with survival. Only tumor stage was statistically
associated with survival (stage I-II HR2.82 p = 0.019;
I-III HR4.44 p = 0.0001); the median survival times
were “not reached”, 2.69 and 1.80 years, for tumor
stage I, II and III, respectively.
In univariate Cox analysis, GAPDH gene expression,
measured by RQ-PCR, was found significantly correlated
with patient survival (HR1.30; 95%CI 1.00-1.69; p = 0.050)
(Figure 1A, forest plot top line). Kaplan-Meier survival
plot (Figure 2), where patients are divided by GAPDH
gene expression level being higher or lower than the me-
dian level, shows that patients with lower GAPDH levels
had a better survival than patients with higher GAPDH
levels.
In multivariate Cox model adjusted for stage, GAPDH
HR value was lower than in univariate model and not
significant (HR1.20; 95%CI .89-1.63; p = 0.23) (Figure 1B,
forest plot top line), and only tumor stage I-III was
significantly correlated with survival (stage I-II HR2.36
p = 0.069; I-III HR4.22 p = 0.0002).A
Figure 1 Forest plots for GAPDH Hazard Ratio results in all datasets. F
regression results in our patient dataset (IST) RQ-PCR measurements, and in
marker square sizes according to forest plot standards [32]. A) Comparison
same comparison adjusting for tumor stage in the models. Patient number
A general agreement of our data with most microarray data can be observ
different HR but also its low cumulative survival. Furthermore, in B), tumor
affecting any microarray dataset result.Verification in the public microarray datasets
Cox regression analysis for GAPDH gene expression in
the microarrays datasets are summarized in the two for-
est plots (Figure 1A and B, before and after adjusting for
tumor stage in the model, respectively), and compared
with GAPDH results for our patient (IST) . Cumulative
survivals and dataset sizes are also reported in the plots.
According to Figure 1A, the GAPDH HR and 95% CI
values found in our patients were in good agreement with
the values calculated in the microarrays datasets, with the
exception of the Bo2013 dataset (HR1.00 p = 0.97). This
latter also featured a five years cumulative survival lower
(0.42) than most other datasets (in the range of 0.50-0.84)
(Table 2) and an unusual high mortality even in lowest
tumor stage patients (stage I: 130 patients, 71 deceased,
55%). In Figure 3 the Kaplan-Meier survival plots for the
microarray datasets are reported, where patients are di-
vided by GAPDH gene expression level being higher or
lower than the median level. A substantial agreement can
be observed among all Kaplan-Meier plots, and with
the corresponding Kaplan-Meier plots for our patients
(Figure 2).
By comparing our regression results before and after
adjusting for tumor stage (respectively Figure 1A and B),
it results that HR for GAPDH gene expression was
mostly independent from stage in microarray datasets,
while in our patient data (IST), after adjusting for tumor
stage, HR value was decreased and not significant. In
multivariate Cox proportional hazard model together
with GAPDH gene expression, tumor stage HR values
were found high (as expected) for most microarray
datasets (stage: Sh2008 I-II HR2.60 p < 0.0001, I-III
HR4.78 p < 0.0001;To2009 I-II + III HR2.29 p = 0.004;B
orest plots style comparison for GAPDH Hazard Ratio (HR) Cox
the public microarray datasets. Confidence intervals (95%) bars and
of HR calculated by Cox models without adjusting for tumor stage; B)
(N pts) and five-years cumulative survival (Surv 5y) are also reported.
ed. Botling 2013 data is an exception, in both forest plots, due to its




    
Figure 3 Kaplan-Meier survival plots for the microarray datasets. Kapa
by having GAPDH probe expression levels higher (red line) or lower (black
probe was plotted due to GAPDH probe unavailability (see in Methods). It c
our RQ-PCR results (Figure 2), with the exception of Botling 2013 dataset.
Figure 2 Kaplan-Meier survival plot for our patient dataset
(IST). Kapan-Meier plots for IST dataset, where patients were divided
by having GAPDH RQ-PCR levels higher (red line) or lower (black
line) than the median level.
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HR1.69 p = 0.2). However, for Bo2013 dataset, tumor
stage HR values were lower than in the other datasets,
and not significant for stage I-II despite the high patient
and event numbers (stage Bo2013 I-II HR1.28 p = 0.32;
I-III HR1.88 p = 0.01).
In agreement with the rationale provided in the
Methods section, the TPI1 gene HR value and CI in
Ro2009 dataset were found to be very similar to the
GAPDH gene results in the other datasets.
Comparing the subset of the patients that did not re-
ceive adjuvant treatments, with the whole dataset in the
Sh2008, we found that GAPDH HR was pretty un-
changed (GAPDH: untreated patients HR1.49, whole
dataset HR1.54, Figure 1A). The subset containing adju-
vant treated patients only had a significantly lower cu-
mulative survival (0.38, 95%0.30-0.50 N = 112) than the
untreated patient subset (0.64, 95%.58-.70, N = 330), but
GAPDH HR was still unchanged (adjuvant-treated
GAPDH HR1.57, 95%1.22-2.03, p < 0.0001). Finally, in ran-
dom sampling of subgroups of patients from Sh2008, we
observed that GAPDH HR was not specifically affected
when calculated in subsets featuring low cumulative sur-
vivals (Additional file 2). 
    
  
n-Meier plots for the microarray datasets where patients were divided
line) than the median levels. For the Roepman et al. 2009 dataset, TPI1
an be observed a general agreement among the datasets, and with
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It is well known that lung tumors present with high gly-
colysis level, but it is yet to demonstrate that glycolysis
level, as assessed in resected NSCLC patient tumor sam-
ple, can be a prognostic factor; we think that our results
gave some evidence suggesting its prognostic capabil-
ities. In the present study we assessed the gene expres-
sion level of GAPDH, that has a key role in glucose
breakdown; with our surprise, we found no studies spe-
cifically addressing the prognostic capabilities of GAPDH
gene expression in resected NSCLC samples.
GAPDH protein is known to have also extra-glycolytic
capabilities, being able to move to the nucleus, to sup-
port cell response to stress, and to initiate apoptosis
[18]. However GAPDH gene is always expressed at high
levels, with high glycolysis levels, in NSCLC compared
to normal lung cells; so we think that our GAPDH prog-
nostic results reflect an increased catalytic activity of
GAPDH protein in glucose metabolism. In this sense
our results are in agreement with the studies that are
correlating glucose metabolism to NSCLC prognosis by
using different approaches, among which FDG uptake
level assessment by PET imaging of the tumor before re-
section. Furthermore, on the same reasoning, many
studies in NSCLC are recently addressing the prognostic
value of other key proteins or gene involved in glucose
metabolism, e.g. GLUT1, HK2 [10]. In fact, it is still un-
known which aspects of glycolysis have strong prognos-
tic value in NSCLC, but many available evidences,
including our present study results, support that the
level of glycolysis has indeed prognostic value.
In our study we measured RQ-PCR GAPDH gene ex-
pression levels in the resected tumors from 82 patients
of our hospital and found a significant correlation with
their prognosis. Then we decided to verify this correl-
ation in the largest NSCLC public microarray datasets,
and we found a confirmation of our result. We showed
all results in forest plot style, for an individual compari-
son. In fact, not all the available public data feature the
same accuracy; especially some datasets, e.g. Sh2008, are
better annotated so to be used as a reference in many
studies. Among the confirmations coming from the
microarray datasets, we think that the Sh2008 data gave
a strong support to our results.
Our results for GAPDH also agree with the findings of
a very recent paper from Wang et al. [34] in which the
authors show the prognostic value of some genes corre-
lated with GAPDH (GACC genes) together with GAPDH
itself; Sh2008 was used as verification dataset. Authors
don't show the prognostic performance of GAPDH
alone; however, our results, confirmed on a large num-
ber of public datasets including Sh2008, suggest that
large part of the prognostic performances shown in
Sh2008 have to be attributed to GAPDH alone.In the forest plots we showed the Ro2009 dataset re-
sults too, by plotting its TPI1 gene levels instead of the
unavailable GAPDH ones. Actually this substitution was
based on the strict metabolic relation between the two
catalytic proteins – however the high correlation of the
two genes was verified in the other datasets, and is con-
firmed by other authors too [34]. So, Ro2009 results for
TPI1, very similar to GAPDH results in the other
datasets, can further support that the prognostic capabil-
ities of GAPDH in NSCLC reflect the role of the corre-
sponding enzyme in glucose metabolism.
However one dataset (Bo2013) had a null result for
GAPDH correlation with prognosis (HR = 1.0); this dataset
was also featuring some characteristics different from all
the other ones: i) a low cumulative survival, also at low
tumor stages, and ii) a low tumor stage HR and signifi-
cance, despite the high patient and event numbers. We
have no data supporting a correlation of these characteris-
tics with a strong decrease of HR values for GAPDH, so
we can only conclude that the Bo2013 dataset is different
from the other datasets from more than a single point of
view.
GAPDH HR was not affected when selecting only pa-
tients that had not received any adjuvant therapy; we
performed this comparison in the Sh2008 dataset. This
result was helpful for our data analysis; in fact our pa-
tients had not received radiotherapy or chemotherapy,
but in most microarray datasets the information, whether
adjuvant treatments had been performed or not, was not
available at patient level. Actually, adjuvant treatment
presence could confound a survival analysis because there
is-finally- evidence that it can increase survival also in
lower stages patient [12]. Furthermore, clinicians select
patients with presumed poor prognosis to be referred for
adjuvant therapies-in fact patient selection is one of the
main reasons why retrospective studies cannot address ad-
juvant treatment effectiveness; this selection was resulting
in the low cumulative survival found in Sh2008 adjuvant
treated patient only subset. However, we observed that
this selection probably did not much influence GAPDH
HR value (Additional file 2). So, GAPDH HR insensitivity
to the presence of adjuvant treatments suggests that
GAPDH is still a prognostic factor in adjuvant treated pa-
tients, but is not promising as predictive factor of adjuvant
effectiveness, as performed in Sh2008 patients.
However, in more recent years, some anti-tumor
drugs under investigation are involving tumor metab-
olism, e.g. by reducing glucose availability as metformin
[35], or by directly targeting glycolysis proteins [36]; our re-
sults suggest that in clinical investigations on these drugs,
GAPDH levels in resected NSCLC samples should be in-
vestigated as possible predictor of treatment effectiveness.
From the clinical point of view the GAPDH HR value
found in our patients is interesting; however after tumor
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GAPDH gene expression had some correlation with
tumor stage. Indeed, adjusting for tumor stage in the re-
gression model had small effect on HR calculation in
microarray datasets, suggesting that our patient number
was simply critically too low to overpass the significance
level for HR after adjusting for stage, but that GAPDH
HR is for large part independent from stage. It will be
therefore interesting to investigate how GAPDH could
contribute with FDG uptake level and tumor stage in
building a composite prognostic marker, possibly also
correlating it with the status of known NSCLC onco-
genic genes (PI3K, EGFR, KRAS, ALK, etc.).
Finally, not only our results warn researchers from
using GAPDH as housekeeper gene in NSCLC prognos-
tic studies involving RQ-PCR measurements; we also
suggest that any past NSCLC prognostic study using
GAPDH as housekeeper gene should be considered po-
tentially biased.
In conclusion, GAPDH gene expression level in resected
tumor, as assessed by RQ-PCR or microarray, is an im-
portant prognostic factor in NSCLC, that confirms the
importance of investigating metabolism in lung cancer.Additional files
Additional file 1: GAPDH primer for RQ-PCR and RQ-PCR data.
Primer sequence used for GAPDH RQ-PCR and RQ-PCR data for IST
patients.
Additional file 2: GAPDH HR variation in low survival subsets.
GAPDH Hazard Ratio (HR) variation in low cumulative survival subsets,
investigated by random sampling from Shedden et al. 2008 dataset.
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